Company Encyclopedia
View More
name
Kymera Therapeutics
KYMR.US
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A.
1.930 T
KYMR.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking193/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-32.09%E
    • Profit Margin-674.80%E
    • Gross Margin-2580.68%E
  • Growth ScoreE
    • Revenue YoY-50.05%E
    • Net Profit YoY-76.22%E
    • Total Assets YoY6.49%B
    • Net Assets YoY5.97%B
  • Cash ScoreE
    • Cash Flow Margin-14.82%D
    • OCF YoY-50.05%E
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreA
    • Gearing Ratio14.14%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Kymera rises on upcoming data release for eczema asset KT-621

    Kymera Therapeutics' stock rose ~9% after announcing the release of phase 1b data for its eczema candidate KT-621 on Dec. 8. KT-621 is an oral STAT6 degrader, targeting Th2 inflammation in allergic diseases. The release will include a press release and webcast. Potential indications include asthma and COPD.

    businessinsider·
    US
    KYMR
    +0.59%
    businessinsider·
    US
    KYMR
    +0.59%

    Piper Sandler Sticks to Their Buy Rating for Kymera Therapeutics (KYMR)

    Piper Sandler's Edward Tenthoff reiterated a Buy rating for Kymera Therapeutics with a $98 price target. Tenthoff, who covers the Healthcare sector, has an average return of -8.8% and a 33.95% success rate. Morgan Stanley also maintained a Buy rating with a $73 price target. The report highlights investment insights and research tools offered by TipRanks.

    Tip Ranks·
    US
    KYMR
    +0.59%
    Tip Ranks·
    US
    KYMR
    +0.59%

    Kymera initiates dosing in KT-621 Phase IIb atopic dermatitis trial

    Kymera Therapeutics has started dosing in its BROADEN2 Phase IIb clinical trial for the oral STAT6 degrader, KT-621, in moderate to severe atopic dermatitis patients. The trial involves around 200 patients and aims to assess the safety, efficacy, and tolerability of KT-621 over 16 weeks. Primary and secondary endpoints include changes in EASI scores and pruritus improvement. Data is expected by mid-2027. The company also plans to launch a Phase IIb asthma trial in early 2026.

    WorldPharmaceuticals·
    US
    KYMR
    +0.59%
    WorldPharmaceuticals·
    US
    KYMR
    +0.59%

    Kymera Therapeutics (KYMR) Gets a Buy from Truist Financial

    Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Kymera Therapeutics with a price target of $80. UBS's Eliana Merle also issued a Buy rating, while TR | OpenAI reiterated a Hold rating on November 15. Devarakonda, focusing on the Healthcare sector, has an average return of 13.9% and a 54.98% success rate on recommended stocks.

    Tip Ranks·
    US
    KYMR
    +0.59%
    Tip Ranks·
    US
    KYMR
    +0.59%

    Kymera Therapeutics Launches Phase 2b Trial of Oral STAT6 Degrader KT-621 in Atopic Dermatitis

    Kymera Therapeutics has started dosing in the Phase 2b BROADEN2 trial for KT-621, an oral STAT6 degrader, in moderate to severe atopic dermatitis. Results are expected by mid-2027. The Phase 1b trial results are anticipated in December 2025. A Phase 2b trial for asthma will begin in early 2026. No results have been reported yet.

    Reuters·
    US
    KYMR
    +0.59%
    Reuters·
    US
    KYMR
    +0.59%
    © 2025 Longbridge｜Disclaimer